Taiwan Biomaterial Co., Ltd. (6649) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Taiwan Biomaterial Co., Ltd. (6649:TWSE), powered by AI.

Current Price
$37.45
Sector
Healthcare
What is the Taiwan Biomaterial Co., Ltd. stock price forecast?

Taiwan Biomaterial Co., Ltd. is currently trading at $37.45. View real-time AI analysis on Alpha Lenz.

What is Taiwan Biomaterial Co., Ltd. insider trading activity?

View the latest insider trading data for Taiwan Biomaterial Co., Ltd. on Alpha Lenz.

What is Taiwan Biomaterial Co., Ltd.'s P/E ratio?

View Taiwan Biomaterial Co., Ltd.'s valuation metrics on Alpha Lenz.

Taiwan Biomaterial Co., Ltd.

TWSE · 6649
NT$37.45-0.55(-1.45%)
Ask about Taiwan Biomaterial Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Taiwan Biomaterial Co., Ltd.'s ROE is 9.0%. Explore profitability and growth together.

Ask for details

Company Overview

Taiwan Biomaterial Co., Ltd. is a developer and manufacturer of advanced implantable medical equipment, operating within the healthcare supplies sector. The company specializes in the research, development, and production of high-end implantable devices, including biomaterials such as foam-based medical components, specialized interventional devices for stroke treatment, and regenerative products for early degenerative arthritis. Taiwan Biomaterial’s core strength lies in its close collaboration with clinicians to identify unmet medical needs encountered in surgical practice, which then guides its innovation pipeline from concept through clinical validation to commercial rollout. By leveraging a multidisciplinary technological base and robust regulatory compliance, the company brings novel products to global markets, partnering with international brands for distribution or licensing to maximize the value of its proprietary technologies. Taiwan Biomaterial Co., Ltd. plays a significant role in advancing biomaterials and interventional therapies, contributing to the broader medical device industry with a focus on clinical efficacy and market impact.

SectorHealthcare
IndustryMedical Devices
Employees35

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$220.40MRevenue
0.00Shares Out
35Employees

Margins

61.16%Gross
34.62%EBITDA
27.60%Operating
26.74%Pre-Tax
26.74%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

20.08%Rev 3Yr
64.90%Rev 5Yr
33.68%Op Inc 3Yr
N/AOp Inc 5Yr
20.41%Net Inc 3Yr
N/ANet Inc 5Yr

Returns

7.89%ROA
8.99%ROE
7.98%ROIC

Financial Health

NT$258.40MCash & Cash Equivalents
NT$-153.54MNet Debt
15.31%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Taiwan Biomaterial Co., Ltd. (ticker: 6649) is a company listed on TWSE in the Healthcare sector (Medical Devices). It has approximately 35 employees.

The current price is 37.45 with a P/E ratio of -x and P/B of -x.

ROE is 8.99% and operating margin is 27.60%. Annual revenue is $220M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Taiwan Biomaterial Co., Ltd. (6649) Stock Forecast 2026 $37.45 — Price, Financials & Analyst Targets | Alpha Lenz